• 1
    Tanabe M, Shimazu M, Wakabayashi G, Hoshino K, Kawachi S, Kadomura T, et al. Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 2002; 73: 19591961.
  • 2
    Sekido H, Matsuo K, Takeda K, Morioka D, Kubota T, Tanaka K, et al. Successful adult ABO-incompatible liver transplantation: therapeutic strategy for thrombotic microangiopathy is the key to success. Transplantation 2003; 75: 16051607.
  • 3
    Usuda M, Fujimori K, Koyamada N, Fukumori T, Sekiguchi S, Kawagishi N, et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation 2005; 79: 1216.
  • 4
    Egawa H, Oike F, Buhler L, Shapiro AM, Minamiguchi S, Haga H, et al. Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. Transplantation 2004; 77: 403411.
  • 5
    Haga H, Egawa H, Shirase T, Miyagawa A, Sakurai T, Minamiguchi S, et al. Periportal edema and necrosis as diagnostic histological features of early humoral rejection in ABO-incompatible liver transplantation. Liver Transpl 2004; 10: 1627.
  • 6
    Morioka D, Sekido H, Kubota K, Sugita M, Tanaka K, Togo S, et al. Antibody-mediated rejection after adult ABO-incompatible liver transplantation remedied by gamma-globulin bolus infusion combined with plasmapheresis. Transplantation 2004; 78: 12251228.
  • 7
    Collins AB, Schneeberger EE, Pascual MA, Saidman SL, Williams WW, Tolkoff-Rubin N, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 22082214.
  • 8
    Behr TM, Feucht HE, Richter K, Reiter C, Spes CH, Pongratz D, et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant 1999; 18: 904912.
  • 9
    Magro CM, Pope Harman A, Klinger D, Orosz C, Adams P, Waldman J, et al. Use of C4d as a diagnostic adjunct in lung allograft biopsies. Am J Transplant 2003; 3: 11431154.
  • 10
    Ruiz P, Garcia M, Pappas P, Berney T, Esquenazi V, Kato T, et al. Mucosal vascular alterations in isolated small-bowel allografts: relationship to humoral sensitization. Am J Transplant 2003; 3: 4349.
  • 11
    Yoshizawa A, Sakamoto S, Ogawa K, Kasahara M, Uryuhara K, Oike F, et al. New protocol of immunosuppression for liver transplantation across ABO barrier: the use of rituximab, hepatic arterial infusion, and preservation of spleen. Transplant Proc 2005; 37: 17181719.
  • 12
    Demetris AJ, Nakamura K, Yagihashi A, Iwaki Y, Takaya S, Hartman GG, et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992; 16: 671681.
  • 13
    International Panel. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658663.
  • 14
    Zwirner J, Felber E, Schmidt P, Riethmuller G, Feucht HE. Complement activation in human lymphoid germinal centres. Immunology 1989; 66: 270277.
  • 15
    Gugenheim J, Samuel D, Reynes M, Bismuth H. Liver transplantation across ABO blood group barriers. Lancet 1990; 336: 519523.
  • 16
    Farges O, Kalil AN, Samuel D, Saliba F, Arulnaden JL, Debat P, et al. The use of ABO-incompatible grafts in liver transplantation: a life-saving procedure in highly selected patients. Transplantation 1995; 59: 11241133.
  • 17
    Straatsburg IH, Boermeester MA, Wolbink GJ, van Gulik TM, Gouma DJ, Frederiks WM, Hack CE. Complement activation induced by ischemia-reperfusion in humans: a study in patients undergoing partial hepatectomy. J Hepatol 2000; 32: 783791.
  • 18
    Krukemeyer MG, Moeller J, Morawietz L, Rudolph B, Neumann U, Theruvath T, et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004; 78: 6570.
  • 19
    Moeller J, Krukemeyer MG, Morawietz L, Schmeding M, Dankof A, Neumann U, et al. Molecular case report: IgVH analysis in acute humoral and cellular liver allograft rejection suggests a selected accumulation of effector B cells and plasma cells. Virchows Arch 2005; 446: 325332.
  • 20
    Tanaka Y, Haga H, Egawa H, Okuno T, Miyagawa-Hayashino A, Tsuruyama T, et al. Intragraft expression of recipient-type ABO blood group antigens: long-term follow-up and histological features after liver transplantation. Liver Transpl 2005; 11: 547554.
  • 21
    Nakamura K, Murase N, Becich MJ, Furuya T, Todo S, Fung JJ, et al. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol 1993; 142: 13831391.
  • 22
    Takaya S, Bronsther O, Iwaki Y, Nakamura K, Abu-Elmagd K, Yagihashi A, et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992; 53: 400406.
  • 23
    Wu T, Abu-Elmagd K, Bond G, Demetris AJ. A clinicopathologic study of isolated intestinal allografts with preformed IgG lymphocytotoxic antibodies. Hum Pathol 2004; 35: 13321339.